BMY
Price
$48.52
Change
+$0.86 (+1.80%)
Updated
Jul 10 closing price
Capitalization
109.66B
20 days until earnings call
RHHBY
Price
$40.87
Change
+$0.78 (+1.95%)
Updated
Jul 9 closing price
Capitalization
250.69B
13 days until earnings call
Interact to see
Advertisement

BMY vs RHHBY

Header iconBMY vs RHHBY Comparison
Open Charts BMY vs RHHBYBanner chart's image
Bristol-Myers Squibb
Price$48.52
Change+$0.86 (+1.80%)
Volume$14.73M
Capitalization109.66B
Roche Holding
Price$40.87
Change+$0.78 (+1.95%)
Volume$1.01M
Capitalization250.69B
BMY vs RHHBY Comparison Chart in %
Loading...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMY vs. RHHBY commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and RHHBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (BMY: $48.52 vs. RHHBY: $41.22)
Brand notoriety: BMY: Notable vs. RHHBY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 105% vs. RHHBY: 72%
Market capitalization -- BMY: $109.66B vs. RHHBY: $250.69B
BMY [@Pharmaceuticals: Major] is valued at $109.66B. RHHBY’s [@Pharmaceuticals: Major] market capitalization is $250.69B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 2 FA rating(s) are green whileRHHBY’s FA Score has 2 green FA rating(s).

  • BMY’s FA Score: 2 green, 3 red.
  • RHHBY’s FA Score: 2 green, 3 red.
According to our system of comparison, RHHBY is a better buy in the long-term than BMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 5 TA indicator(s) are bullish while RHHBY’s TA Score has 4 bullish TA indicator(s).

  • BMY’s TA Score: 5 bullish, 5 bearish.
  • RHHBY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BMY is a better buy in the short-term than RHHBY.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а +3.41% price change this week, while RHHBY (@Pharmaceuticals: Major) price change was +1.93% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.39%. For the same industry, the average monthly price growth was +1.04%, and the average quarterly price growth was +11.01%.

Reported Earning Dates

BMY is expected to report earnings on Oct 30, 2025.

RHHBY is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.39% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHBY($251B) has a higher market cap than BMY($110B). RHHBY has higher P/E ratio than BMY: RHHBY (19.46) vs BMY (13.73). RHHBY YTD gains are higher at: 22.106 vs. BMY (-11.172). BMY (19.4B) and RHHBY (19.1B) have comparable annual earnings (EBITDA) . BMY has more cash in the bank: 12.3B vs. RHHBY (7.51B). RHHBY has less debt than BMY: RHHBY (25.4B) vs BMY (41.5B). RHHBY has higher revenues than BMY: RHHBY (60B) vs BMY (45B).
BMYRHHBYBMY / RHHBY
Capitalization110B251B44%
EBITDA19.4B19.1B102%
Gain YTD-11.17222.106-51%
P/E Ratio13.7319.4671%
Revenue45B60B75%
Total Cash12.3B7.51B164%
Total Debt41.5B25.4B163%
FUNDAMENTALS RATINGS
BMY vs RHHBY: Fundamental Ratings
BMY
RHHBY
OUTLOOK RATING
1..100
6261
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
9178
SMR RATING
1..100
3099
PRICE GROWTH RATING
1..100
6051
P/E GROWTH RATING
1..100
5617
SEASONALITY SCORE
1..100
6548

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (5) in the Pharmaceuticals Major industry is in the same range as RHHBY (15) in the null industry. This means that BMY’s stock grew similarly to RHHBY’s over the last 12 months.

RHHBY's Profit vs Risk Rating (78) in the null industry is in the same range as BMY (91) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to BMY’s over the last 12 months.

BMY's SMR Rating (30) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBY (99) in the null industry. This means that BMY’s stock grew significantly faster than RHHBY’s over the last 12 months.

RHHBY's Price Growth Rating (51) in the null industry is in the same range as BMY (60) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to BMY’s over the last 12 months.

RHHBY's P/E Growth Rating (17) in the null industry is somewhat better than the same rating for BMY (56) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew somewhat faster than BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYRHHBY
RSI
ODDS (%)
Bearish Trend 1 day ago
43%
Bearish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
52%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bullish Trend 1 day ago
46%
Bullish Trend 2 days ago
40%
MACD
ODDS (%)
Bullish Trend 1 day ago
52%
Bearish Trend 2 days ago
54%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
52%
Bearish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
51%
Bullish Trend 2 days ago
51%
Advances
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 17 days ago
52%
Declines
ODDS (%)
Bearish Trend 4 days ago
54%
Bearish Trend 3 days ago
46%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 2 days ago
35%
Aroon
ODDS (%)
Bullish Trend 1 day ago
45%
Bullish Trend 2 days ago
36%
View a ticker or compare two or three
Interact to see
Advertisement
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DUHP36.320.16
+0.44%
Dimensional US High Profitability ETF
FDEV32.400.04
+0.12%
Fidelity International Multifactor ETF
XFIX51.51N/A
N/A
F/m Opportunistic Income ETF
CGGE29.32-0.03
-0.10%
Capital Group Global Equity ETF
MUJ10.92-0.05
-0.46%
Blackrock Muniholdings NEW Jersey Quality Fund

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+1.80%
PFE - BMY
53%
Loosely correlated
+0.86%
GILD - BMY
46%
Loosely correlated
+1.15%
AMGN - BMY
43%
Loosely correlated
+1.30%
JNJ - BMY
43%
Loosely correlated
+0.90%
GSK - BMY
41%
Loosely correlated
+1.38%
More

RHHBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHBY has been loosely correlated with RHHVF. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHBY jumps, then RHHVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBY
1D Price
Change %
RHHBY100%
+0.86%
RHHVF - RHHBY
65%
Loosely correlated
+1.12%
NVS - RHHBY
37%
Loosely correlated
+0.64%
JNJ - RHHBY
37%
Loosely correlated
+0.90%
RHHBF - RHHBY
32%
Poorly correlated
-2.55%
BMY - RHHBY
28%
Poorly correlated
+1.80%
More